文献速递技术与安全介入PET

放射诊疗一体化在癌症诊断与管理中的应用

Radiotheranostics in Cancer Diagnosis and Management.
PubMed 文献 · Radiology · 2018-01-01

本文综述放射诊疗一体化的概念、历史与近期进展,指出放射性碘是临床应用近75年的经典诊疗一体化药物,近年神经内分泌肿瘤和前列腺癌的放射诊疗一体化取得重要进展,多种放射诊疗配对药物有望在近期获批,并讨论了当前挑战与前景。

要点

  • 放射诊疗一体化将靶向诊断与治疗配对使用,先成像「看见」病灶再给药物治疗同一病灶。
  • 放射性碘是经典放射诊疗一体化药物,已在甲状腺疾病临床管理中应用近75年。
  • 神经内分泌肿瘤和前列腺癌的放射诊疗一体化近年取得重要进展,多种配对药物有望近期获批。

核心结论

  • 放射诊疗一体化策略可提高疗效、使不良事件可控、改善患者结局并降低总体费用。
  • 多种放射诊疗配对药物的监管批准有望在近期到来。
  • 需要持续支持研发以跟上放射诊疗一体化创新的势头,监管与报销机构需简化要求以促进药物从实验室到临床的转化。

研究设计与样本

  • 综述,讨论放射诊疗一体化的概念、历史、近期进展、当前挑战与前景,未报告检索范围与纳入文献。

关键影像表现/征象

  • 放射诊疗一体化平台包括一个「看见」病灶的成像部分,随后给予「治疗」同一病灶的配对治疗药物。
  • 放射性碘是经典放射诊疗一体化药物,临床应用近75年。
  • 神经内分泌肿瘤和前列腺癌等疾病的放射诊疗一体化近年取得重要进展。

临床应用与阅片要点

  • 放射诊疗一体化的成像部分用于「看见」病灶,随后给予配对治疗药物治疗同一病灶。
  • 放射性碘作为经典放射诊疗一体化药物已用于甲状腺疾病的临床管理近75年。
  • 多种放射诊疗配对药物有望近期获批,研发、监管与报销层面需协同推进其临床转化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

The fundamental foundation for precision medicine is accurate and specific targeting of cancer cells. Advances in the understanding of cancer biology, developments in diagnostic technologies, and expansion of therapeutic options have all contributed to the concept of personalized cancer care. Theranostics is the systematic integration of targeted diagnostics and therapeutics. The theranostic platform includes an imaging component that "sees" the lesions followed by administration of the companion therapy agent that "treats" the same lesions. This strategy leads to enhanced therapy efficacy, manageable adverse events, improved patient outcome, and lower overall costs. Radiotheranostics refers to the use of radionuclides for the paired imaging and therapy agents. Radioiodine is the classic radiotheranostic agent that has been used clinically in management of thyroid diseases for nearly 75 years. More recently there have been major exciting strides in radiotheranostics for neuroendocrine tumors and prostate cancer, among other conditions. Regulatory approval of a number of radiotheranostic pairs is anticipated in the near future. Continued support will be needed in research and development to keep pace with the current momentum in radiotheranostics innovations. Moreover, regulatory and reimbursement agencies need to streamline their requirements for seamless transfer of the radiotheranostic agents from the bench to the bedside. In this review, the concept, history, recent developments, current challenges, and outlook for radiotheranostics in the treatment of patients with cancer will be discussed. © RSNA, 2018.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Jadvar H, Chen X, Cai W, et al. Radiotheranostics in Cancer Diagnosis and Management. Radiology. 2018. PMID: 29356634. doi:10.1148/radiol.2017170346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。